Max Healthcare Institute Limited (NSE:MAXHEALTH)
1,067.40
-41.00 (-3.70%)
Apr 25, 2025, 3:30 PM IST
Max Healthcare Institute Revenue
Max Healthcare Institute had revenue of 18.68B INR in the quarter ending December 31, 2024, with 39.95% growth. This brings the company's revenue in the last twelve months to 65.42B, up 25.86% year-over-year. In the fiscal year ending March 31, 2024, Max Healthcare Institute had annual revenue of 54.06B with 18.49% growth.
Revenue (ttm)
65.42B
Revenue Growth
+25.86%
P/S Ratio
15.87
Revenue / Employee
3.35M
Employees
19,500
Market Cap
1,038.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 54.06B | 8.43B | 18.49% |
Mar 31, 2023 | 45.63B | 6.26B | 15.90% |
Mar 31, 2022 | 39.37B | 14.29B | 56.96% |
Mar 31, 2021 | 25.08B | 14.49B | 136.82% |
Mar 31, 2020 | 10.59B | -6.35B | -37.48% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Max Healthcare Institute News
- 26 days ago - Pharma and healthcare stocks: Macquarie turns bullish on Sun Pharma, Cipla, Lupin; bearish on Apollo Hospitals, Max Healthcare - Business Upturn
- 5 weeks ago - Max Healthcare unit merger aims at improved cash flow and reduced compliance burden - Business Upturn
- 6 weeks ago - Max Healthcare to enter long-term service agreement for New Delhi Hospital - Business Upturn
- 7 weeks ago - Top stocks to buy: Stock recommendations for the week starting March 3 - The Times of India
- 2 months ago - Max Healthcare shares surge 2% as UBS upgrades to ‘Buy’ rating with target price of Rs 1,200 - Business Upturn
- 2 months ago - UBS upgrades Max Healthcare to ‘Buy’, raises target to ₹1,200 on strong expansion visibility - Business Upturn
- 2 months ago - Q3 2025 Max Healthcare Institute Ltd Earnings Call Transcript - GuruFocus
- 3 months ago - Max Healthcare shares in focus: HSBC maintains Hold, sees limited downside post Q3 operational beat - Business Upturn